Abstract 2474
Background
Uveal melanoma is the most common primary intraocular malignancy in adults. Almost half of patients with uveal melanoma may die from metastatic disease and the most frequent site of metastases is the liver. It is considered as an inflammatory phenotype. NFκB plays a connecting link between the inflammation and cancer. c-Rel and p50 are together considered as a heterodimer (c-Rel/p50) which plays an important role in inflammation and cancer progression. Therefore, the aim of the study is to detect c-Rel/p50 heterodimer expression in the tumour microenvironment of uveal melanoma and its prognostic significance.
Methods
Evaluation of c-Rel/p50 heterodimer expression was performed in 75 formalin fixed uveal melanoma tissues by using immunohistochemistry. Transcriptional analysis was performed on 58 fresh tissues by real-time PCR (q-PCR). Co-Immunoprecipitation (Co-IP) was done on 10 representative cases to assess the presence of c-Rel/p50 heterodimer and validation of immunohistochemistry results was performed by western blotting. Results were then correlated with clinicopathological parameters.
Results
Immunoexpression of c-Rel+/p50+ is localized to the cytoplasm in normal choroid whereas both cytoplasmic and nuclear expression was seen in 33.33% cases. At the transcriptional level, upregulation of c-Rel+/p50+ heterodimer was shown in 43.10%. Expression of both cytoplasmic and nuclear c-Rel+/p50+ heterodimer were found to have significant correlation with cases having tumour infiltrating lymphocytes, macrophages (CD68+) and high pigmentation. There was a statistically significant difference in the overall survival of patients with nuclear and cytoplasmic expression of c-Rel+/p50+ heterodimer (p < 0.05).
Conclusions
We conclude that c-Rel+/p50+ heterodimer may be used as a poor prognostic indicator of survival outcome in uveal melanoma. Further translational and validation studies are required to confirm its usage as a therapeutic drug target in metastatic uveal melanoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract